

INFORMAZIONI PERSONALI



Alongi Pierpaolo

-  20128 Cefalù (Italia)
-  (+39) 3280862049
-  alongi.pierpaolo@gmail.com

Sesso Maschile | Data di nascita 13/12/1984

ESPERIENZA PROFESSIONALE

10/06/2016–alla data attuale

Responsabile del Servizio di Medicina Nucleare (Unità Complessa di Diagnostica per immagini e Medicina Nucleare - Direttore Prof.M.Midiri)
Fondazione G.Giglio, Cefalù (Italia)

- Resp. Impianto radiologico (Medicina Nucleare - PET e SPECT), Resp. sec art.9 ed art. 8 del D.Lgs n.187/00 per radioprotezione e assicurazione di qualità).
- Referente di punta per programmazione/gestione delle attività cliniche e scientifiche - Medicina Nucleare - supervisione del Direttore dell'UO di Diagnostica per immagini e Medicina Nucleare, prof.M.Midiri.

11/11/2015–alla data attuale

Dirigente Medico in Medicina Nucleare presso Fondazione Instituto G.Giglio di Cefalu

17/05/2015–10/2015

Medico Specialista in Medicina Nucleare presso IRCCS Ospedale San Raffaele, Milano

01/09/2013–01/03/2014

Honorary Clinical Researcher - Training in PET/MRI, Radionuclide Therapy
University College London Hospital, London (Regno Unito)

[Documenti collegati reference letter UCLH.pdf](#)

17/05/2010–17/05/2015

Specializzando in Medicina Nucleare

Università Milano-Bicocca, Milano (Italia)

Attività lavorativa svolta presso:

Ospedale San Raffaele di Milano (4/5 anni)

Ospedale San Gerardo di Monza (6mesi)

Ospedale Niguarda Ca Granda, Milano (6mesi)

[Documenti collegati Alongi reference Perani.pdf, Reference letter OSR.pdf](#)

ISTRUZIONE E FORMAZIONE

17/05/2010–17/05/2015

Specialista in Medicina Nucleare

Università Milano-Bicocca, Milano (Italia)

28/05/2015 Specializzazione in Medicina Nucleare. Votazione 70/70 e lode. Tesi sperimentale dal titolo: ALZHEIMER'S DISEASE: ¹⁸F-FDG AND AMYLOID PET AS IN VIVO BIOMARKERS FOR THE RISK PREDICTION OF MCI PROGRESSION

Percorso formativo multidisciplinare in area radiologica con attività formativa in Medicina Nucleare (4 anni), Radiologia (6 mesi) e Radioterapia (6 mesi).

Attività formativa svolta presso enti convenzionati:



- Ospedale San Raffaele-IRCCS, Milano (3 anni e 6 mesi)

- Ospedale Niguarda Cà Granda, Milano (6 mesi)

. Ospedale Niguarda, Monza (6 mesi)

Esperienze all'estero:

Institute of Nuclear Medicine of UCLH, London, UK (6 mesi)

09/2003–10/2009

Laurea in Medicina e Chirurgia

Università degli studi di Palermo, Palermo (Italia)

Titolo tesi sperimentale: Il management del paziente con carcinoma della tiroide: i nuovi orientamenti diagnostici, la terapia con 131I e le terapie alternative

Votazione 100/110 con mensione.

COMPETENZE PERSONALI

Lingua madre italiano

Altre lingue	COMPRENSIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
inglese	B2	B2	B2	B2	C1

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato

Quadro Comune Europeo di Riferimento delle Lingue

Competenze organizzative e gestionali

- Principal Investigator - Studio PASS1 - Piramal Imaging
- Editor Rivista societaria AIMN-Info
- Fondatore e Coordinatore Nazionale del gruppo AIMN Giovani (Associazione Italiana Medicina Nucleare), dal 03/2013 ad oggi. (http://www.aimn.it/?page_id=963)
- Responsabile pedagogia medica Segretariato Italiano Studenti di Medicina (SISM, Palermo), dal 01/2010 al 01/2012.
- Consigliere di Facoltà - Medicina e Chirurgia, Università degli studi di Palermo, 2008.

Competenze professionali

- Aree di interesse: Imaging Diagnostico, Oncologia, Neurologia.
- Diagnostica: PET/CT, PET/MRI, Medicina Nucleare convenzionale (SPECT, SPECT/CT, gamma camere, gamma-probe), TC, MRI
- Medico Refertatore di più di 3000 esami PET/CT whole-body e PET/CT-Cerebrale
- Radiofarmaci utilizzati in campo diagnostico: 18F-FDG, 18F-Colina, 18F-Fluoride, 18F-Florbetapir, 18F-Florbetaben, 11C-Colina, 11C-PK, 11C-PIB, 68Ga Dotataate, 99TC-Pertechnetato, 99TC-MDP, 99TC-Tetrafosmina, 99TC-DTPA, 99TC-DMSA, 123I-MIBG, 111I-Pentetetotide
- Terapia Radiometabolica: Ra223, 131I, 131I MIBG, 77Lu-Dotataate, Radioimmunoterapia (Zevalin)
- **Trainer Neuraceq**, Florbetaben (18F) - Piramal Imaging
- Investigator training GCP

[Documenti collegati](#) Piramal trainer certificate.pdf, Pierpaolo Alongi - GCP training.pdf

Competenze digitali

- Workstation Diagnostic Imaging : Impax(Agfa), Xeleris (GE), Advantage Workstation(GE).
- Statistical Parametric Mapping (SPM8)
- Analisi statistiche: SPSS 20.0 (IBM).
- Office 2003-2011 (Microsoft).



ULTERIORI INFORMAZIONI

Pubblicazioni

Alongi P, Evangelista L, Caobelli F, Spallino M, Gianolli L, Midiri M, Picchio M. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma. Eur J Nucl Med Mol Imaging. 2017 Aug 22. doi: 10.1007/s00259-017-3811-4. [Epub ahead of print]

Mazzola R, **Alongi P**, Ricchetti F, Fiorentino A, Fersino S, Giaj-Levra N, Salgarello M, Alongi F. 8F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes. Radiol Med. 2017 Aug 28. doi: 10.1007/s11547-017-0804-0.

Iaccarino L, Chiotis K, **Alongi P**, Almkvist O, Wall A, Cerami C, Bettinardi V, Gianolli L, Nordberg A, Perani D. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. J Alzheimers Dis. 2017;59(2):603-614. doi: 10.3233/JAD-170158.

Mapelli P, Broggi S, Incerti E, **Alongi P**, Kirienko M, Fiorino C, Dell Oca I, Fallanca F, Vanoli EG, Di Muzio NG, Gianolli L, Picchio M. FDG-PET/CT Predicts Outcome in Oropharyngeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes. Curr Radiopharm. 2017 Aug 24;10(2):102-110. doi: 10.2174/1874471010666170413151108

Caminiti SP, **Alongi P**, Majno L, Volontè MA, Cerami C, Gianolli L, Comi G, Perani D. Evaluation of an optimized [18 F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders. Eur J Neurol. 2017 May;24(5):687-e26. doi: 10.1111/ene.13269. Epub 2017 Feb 28.

Incerti E, Tombetti E, Fallanca F, Baldissera EM, **Alongi P**, Tombolini E, Sartorelli S, Sabbadini MG, Papa M, De Cobelli F, Mason JC, Gianolli L, Manfredi AA, Picchio M. 18F-FDG PET reveals unique features of large vessel inflammation in patients with Takayasu's arteritis. Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1109-1118. doi: 10.1007/s00259-017-3639-y. Epub 2017 Feb 8.

Caobelli F, Evangelista L, Quartuccio N, Familiari D, Altini C, Castello A, Cucinotta M, Di Dato R, Ferrari C, Kokomani A, Laghai I, Laudicella R, Migliari S, Orsini F, Pignata SA, Popescu C, Puta E, Ricci M, Seghezzi S, Sindoni A, Sollini M, Sturiale L, Svyrdenka A, Vergura V, **Alongi P**, Young Aimn Working Group. Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art. World J Radiol. 2016 Oct 28;8(10):829-845

Fallanca F, **Alongi P**, Incerti E, Gianolli L, Picchio M, Kayani I, Bomanji JB. Reply to letter of Adams and Kwee: Critical considerations on the predictive value of end-of-treatment FDG/PET in lymphoma. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):344-345. doi: 10.1007/s00259-016-3554-7.

Natale Quartuccio, Byung Hyun Byun, **Pierpaolo Alongi**, Federico Caobelli, Chang-Bae Kong, Sang Moo Lim, Angelina Cistaro. Assessment of response to treatment in paediatric bone sarcomas by



means of PET imaging. Clinical and Translational Imaging 4 (1), 41-55

Dodich A, Cerami C, Iannaccone S, Marcone A, **Alongi P**, Crespi C, Canessa N, Andreotta F, Falini A, Cappa SF, Perani D. Neuropsychological and FDG-PET profiles in VGKC autoimmune limbic encephalitis. Brain Cogn. 2016 Oct;108:81-7. doi: 10.1016/j.bandc.2016.07.010.

Alongi P, Caobelli F, Gentile R, Stefano A, Russo G, Albano D, Baldari S, Gilardi MC, Midiri M. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):224-233. doi: 10.1007/s00259-016-3500-8.

Fallanca F, **Alongi P**, Incerti E, Gianolli L, Picchio M, Kayani I, Bomanji J. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC). Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1837-48. doi: 10.1007/s00259-016-3390-9.

Incerti E, Fodor A, Mapelli P, Fiorino C, **Alongi P**, Kirienko M, Giovacchini G, Busnardo E, Gianolli L, Di Muzio N, Picchio M. Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes? J Nucl Med. 2015 Dec;56(12):1836-42. doi: 10.2967/jnumed.115.163741

Natale Quartuccio, Byung Hyun Ryun, Pierpaolo Alongi, Federico Caobelli,
Chang-Bae Kong, Sang Moo Lim & Angelina Cistaro; Assessment of response to treatment in paediatric bone sarcomas by means of PET imaging .Clin Transl Imaging . 2015 Nov. DOI 10.1007/s40336-015-0160-9

Caobelli F, **Alongi P**, Evangelista L, Picchio M, Saladini G, Rensi M, Geatti O, Castello A, Iashar L, Popescu C, Dolci C, Crivellaro C, Seghezzi S, Kirienko M, De Biasi V, Coccilillo F, Quartuccio N, Working Group Young AIMN: Predictive value of 18F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicenter study.Eur J Nucl Med Mol Imaging. 2015 Sep 18. DOI: 10.1007/s00259-015-3184-5

Alongi P, Picchio M, Zattoni F, Spallino M, Gianolli L, Saladini G, Evangelista Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. EJNMMI. Aug 2015. PMID:26268680. DOI 10.1007/s00259-015-3159-6

Elena Incerti, Andrei Fodor, Margarita Kirienko, Claudio Fiorino, **Pierpaolo Alongi**, Genoveffa Berardi, Paola Mapelli, Nadia Di Muzio, Luigi Gianolli,Maria Picchio: May 11C-Choline PET/CT predict tumor response after radiotherapy on lymph node recurrence of prostate cancer patients?J Nucl Med 2015 56:513.

Cistaro A, Niccoli Asabella A, Coppolino P, Quartuccio N, Altini C, Cucinotta M, **Alongi P**, Balma M, Sanfilippo S, Buschiazzo A, Piccardo A, Fanelli M, Sambuceti G, Bomanji J, Baldari S, Bisi G, Fanti S, Rubini G: Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience. Hell J Nucl Med. 2015 Jul 20. pii: s002449910202. PMID: 26187207

Alongi P, Zanoni L, Incerti E, Fallanca F, Mapelli P, Papathanasiou N, Gianolli L, Picchio M, Bomanji J. : *18F-FDG PET/CT for Early Postradiotherapy Assessment in Solitary Bone Plasmacytomas.* Clin Nucl Med. 2015 May 25. [Epub ahead of print] PMID: 26018693

Francesco Fraioli, Ananth Shankar, Darren Hargrave, Harpreet Hyare, Mark N Gaze, Ashley M Groves, **Pierpaolo Alongi**, Sara Stoneham, Sofia Michopoulou, Rizwan Syed, Jamshed B Bomanji: *18F-Fluoroethylcholine (18F-Cho) PET/MRI Functional Parameters in Pediatric Astrocytic Brain Tumors..* Clinical nuclear medicine 09/2014;

Pierpaolo Alongi, Leonardo Iaccarino, Daniela Perani: *PET Neuroimaging: Insights on Dystonia and Tourette syndrome and potential applications.* Frontiers in Neurology 07/2014;

Alongi F, Fodor A, Samanes Gajate AM, **Alongi P**, Longoni L, Gianolli L, Di Muzio N: *PET/CT-Guided Helical Tomotherapy Re-irradiation in an In Field Breast Recurrence.* Journal of Radiotherapy&Medical Oncology. 03/2010; XVI(1):26-30.

Filippo Alongi, Stefano Schipani, Ana Maria Samanes Gajate, Alberto Rosso, Cesare Cozzarini, Claudio Fiorino, **Pierpaolo Alongi**, Maria Picchio, Luigi Gianolli, Cristina Messa, Nadia Di Muzio: *[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months..* Tumori 01/2010; 96(4):613-7.

Filippo Alongi, Angelo Bolognesi, Ana Maria Samanes Gajate, Micaela Motta, Claudio Landoni, Genoveffa Berardi, **Pierpaolo Alongi**, Luigi Gianolli, Nadia Di Muzio: *Inflammatory pseudotumor of mediastinum treated with tomotherapy and monitored with FDG-PET/CT: case report and literature review..* Tumori 96(2):322-6.

Filippo Alongi, Andrei Fodor, Angelo Maggio, Cesare Cozzarini, Claudio Fiorino, Sara Broggi, **Pierpaolo Alongi**, Riccardo Calandrino, Nadia Di Muzio: *Megavoltage CT images of helical tomotherapy unit for radiation treatment simulation: impact on feasibility of treatment planning in a prostate cancer patient with bilateral femoral prostheses..* Tumori 97(2):221-4.

Libri

Book Chapters

Giorgio Treglia, **Pierpaolo Alongi**: *Inflammatory Bowel Diseases. Atlas of PET/CT in Pediatric Patients*, Edited by Angelina Cistaro, 01/2014; Springer., ISBN: 978-88-470-5357-1 (Print) 978-88-470-5358-8

Lavori scientifici presentati a congressi internazionali

Lecturer - CE72: *Genitourinary Cancer and 18F-FDG PET/CT - 18F-FDG PET/CT in Renal and Testicular Cancer - SNMMI June 2017, Denver, CL, USA*

Diagnostic and prognostic value of FDG-PET/CT in recurrent germinal tumor carcinoma . J Nucl Med May 1, 2016 vol. 57 no. supplement 2 522. Oral Presenter, SNMMI June 2016 San Diego, CA,USA

Pierpaolo Alongi, Marianna Spallino, Luigi Gianolli, Maria Picchio: *Renal cell carcinoma: clinical and prognostic value of 18F-FDG-PET/CT after surgery.* Abstract published on J Nucl Med 2015 56:1432. POSTER PRESENTATION - TOP POSTER LIST AWARDED at SNMMI 2015, Baltimore,



Elena Incerti, Andrei Fodor, Margarita Kirienko, Claudio Fiorino, **Pierpaolo Alongi**, Genoveffa Berardi, Paola Mapelli, Nadia Di Muzio, Luigi Gianolli, Maria Picchio: May 11C-Choline PET/CT predict tumor response after radiotherapy on lymph node recurrence of prostate cancer patients? Published on J Nucl Med 2015 56:513: ORAL PRESENTATION at SNMMI 2015, Baltimore, USA.

Pierpaolo Alongi, Marianna Spallino, Elena Incerti, Luigi Gianolli, Maria Picchio: Clinical use of Dynamic 11C-Choline PET/CT in biochemical relapse of prostate cancer after radical treatment. Abstract published on J Nucl Med 2015, 56:1449. POSTER PRESENTATION at SNMMI 2015, Baltimore, USA.

Pierpaolo Alongi, Chiara Cerami, Leonardo Iaccarino, Alessandra Marcone, Valentino Bettinardi, Sandro Iannaccone, Stefano Cappa, Daniela Perani: FDG and amyloid PET in vivo biomarkers for the prediction of MCI progression. AIMN 2015, Rimini 04/2015 . ORAL PRESENTATION

F. Caobelli, **P. Alongi**, L. Evangelista, F. Orsini, A. Castello, I. Laghai, C. Popescu, C. Dolci, S. Seghezzi, G. Puccini, F. Guidoccio, F. Scalorbi, M. Kirienko, N. Quartuccio, V. De Biasi, F. Coccilillo, AIMN GIOVANI Working Group14. AIMN 2015, Rimini 04/2015. ORAL PRESENTATION

P. Alongi. M. Spallino, E. Incerti, L. Gianolli, M. Picchio: Potential clinical use of dynamic 11C-Choline PET/CT for evaluation of prostate cancer in patients with loco-regional failure candidates to radiotherapy. AIMN 2015, Rimini, 04/2015.

Pierpaolo Alongi, Federico Fallanca, Elena Incerti, Luigi Gianolli, Maria Picchio, Jamshed Bomanji: Diagnostic accuracy of 18F-FDG PET/CT for end of treatment evaluation of HL and NHL: A comparison of Deauville Criteria (DC) with International Harmonization Project Criteria (IHPC). EANM Congress 2014, Gothenburg; 10/2014. ORAL PRESENTATION

Pierpaolo Alongi, Elena Incerti, Federico Fallanca, Lucia Zanoni, Paola Mapelli, Luigi Gianolli, Maria Picchio, Jamshed Bomanji: Clinical impact of 18F-FDG PET/CT for early post-radiotherapy assessment in patients with solitary bone plasmacytoma. EANM Congress 2014, Gothenburg; 10/2014. ORAL PRESENTATION

Pierpaolo Alongi: Role of 18F-FDG PET/CT for detection and RT response assessment in patients with solitary bone plasmacytoma. SNMMI Annual Meeting 2014, St.Louise; 06/2014

Incitti Elena, Tombetti Enrico, **Pierpaolo Alongi**, Federico Fallanca, Elena Baldissera, Maria Chiara Di Chio, Silvia Sartorelli, Maria Grazia Sabbadini, Luigi Gianolli, Maria Picchio: Additional role of FDG PET/CT in the assessment of disease activity in Takayasu arteritis. SNMMI 2014, St.Louis; 06/2014

Cistaro A, Coppolino P, Quartuccio N, Cucinotta M, Altini C, **Alongi P**, Balma M, Piccardo A, Morbelli S, Sambuceti G, Baldari S, Bomanji, Rubini G, Fanti S, Bisi G.: Evaluation of the additional value of 18F-FDG-PET/CT over conventional imaging in the staging and restaging of adrenal gland tumors a multicentre study. EMIM 2014 (ESMI); 06/2014



C.Tudisca, S.Punwani, **P. Alongi**, A. Groves, F. Fraioli: *Non-[18F]FDG tracers on PET-MRI: a pictorial review of oncological applications.* ECR 2014; 03/2014

Pierpaolo Alongi: *Impact of time-of-flight (TOF) and point-spread-function (PSF) PET on whole-body oncologic studies.* SNM 2012, Miami; 06/2012

Partecipazione a Corsi e Congressi

- 06-2017 **SNMMI** Annual Meeting, DENVER, USA.
04-2017 AIMN Annual Congress, Rimini, Italy
10/2016 EANM 16- Annual Congress, Barcelona, Spain
06-2016, **SNMMI** Annual Meeting, San Diego, USA.
06-10-06/2015, **SNMMI** Annual Meeting, Baltimore, USA.
16-19/04/2015, Congresso AIMN 2015, Rimini, Italia.
18-22/10/2014, **EANM 14 - Annual Congress**, Gothenburg/SWEDEN
25-27/09/2014 Corso base di Medicina Nucleare in Neurologia, Pesaro, Italia
16/09/2014 AMYVID Reader Training, Lilly - Milano, Italia
21/06/2014: PET Symposium - The New Imaging Frontier. University Hospital Zurich, Switzerland
05/11/2013: Amyvid (Florbetapir 18F) PET Imaging Reader Training - Lilly, London, UK
1-4/03/2013: XI Congresso Nazionale AIMN, Torino, Italia
26/10/2012 XXIII Corso Nazionale di Aggiornamento in Medicina Nucleare ed Imaging Molecolare - Whole Body PET/MRI: Ruolo attuale e sviluppi futuri, Milano, Italia
24/09/2012 Corso Teorico-Pratico - Imaging e Metodologia della Ricerca, Università degli Studi di Milano, Ospedale San Donato, Milano, Italia.
9-13/06/2012: **SNM 2012 Annual Meeting**, Miami, USA
18-21/03/2011: X Congresso Nazionale AIMN, Rimini, Italia

ALLEGATI

- Alongi reference Perani.pdf
- Reference letter OSR.pdf
- Piramal trainer certificate.pdf
- reference letter UCLH.pdf
- Pierpaolo Alongi - GCP training.pdf

